PHARMACEUTICAL 2025

ELI Lilly Co
Rank 119 of 225



PHARMACEUTICAL 2025

ELI Lilly Co
Rank 119 of 225

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 55% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 196%, being 19% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	32,739,700
Cost of Goods Sold	8,418,300
Intangible Assets	11,936,600
Liabilities, Current	28,376,600
Liabilities, Non-Current	36,066,700
Other Assets	16,936,200
Other Compr. Net Income	5,100
Other Expenses	3,169,600
Other Liabilities	0
Other Net Income	0
Other Revenues	45,042,700
Property and Equipment	17,102,400
Research and Development	14,271,000
Selling, General and Administrative Expense	8,593,800

Output Variable	Value in 1000 USD
Assets	78,714,900
Liabilities	64,443,300
Expenses	34,452,700
Revenues	45,042,700
Stockholders Equity	14,271,600
Net Income	10,590,000
Comprehensive Net Income	10,592,550
BaseVar	111,329,350
ECR before LimitedLiability	58%
Economic Capital Ratio	196%